Twelve potential fibrosis markers to differentiate mild liver fibrosis from cirrhosis in patients infected with chronic hepatitis C genotype 1

Andersen, Ellen Sloth; Rühwald, Morten; Moessner, Belinda Klemmensen; Christensen, Peer Brehm; Andersen, Ove; Eugen‐Olsen, Jesper; Weis, Nina

doi:10.1007/s10096-010-1149-y

Cited by 34 publications

(28 citation statements)

References 29 publications

(16 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Natural killer cell-and Th1 cell-mediated immune responses play a role in protection against HCV and hepatitis virus infection (Koziel, 2005). Previous studies reported that the levels of interleukin-8 and interferon-r inducible protein-10 were higher in liver cirrhosis patients compared with healthy subjects (Andersen et al, 2011).…”

Section: Introductionmentioning

confidence: 99%

Interleukin-10 gene promoter polymorphism and risk of liver cirrhosis

Liu

Zhang

et al. 2015

Genet. Mol. Res.

View full text Add to dashboard Cite

ABSTRACT. We conducted a hospital-based case-control study to assess the association between IL-10-592 A/C, IL-10-819 C/T, and IL-10-1082 A/G polymorphisms and the risk of liver cirrhosis in a Chinese population. This 1:1-matched case-control study included 192 patients from the Chinese PLA General Hospital. Genotypes of IL-10-592 A/C, IL-10-819 C/T, and IL-10-1082 A/G were detected by polymerase chain reaction amplification-restriction fragment length polymorphism analysis. Conditional regression analysis showed that individuals carrying the IL-10-1082 G allele had an only slightly increased risk of liver cirrhosis, with an adjusted odds ratio (95% confidence interval) of 2.14 (0.97-1.68). However, we did not identify a significant association between polymorphisms in IL-10-592 A/C and IL-10-819 C/T and the risk of liver cirrhosis. These findings may provide important clues for future studies of early detection screening of liver cirrhosis.

show abstract

Section: Introductionmentioning

confidence: 99%

Interleukin-10 gene promoter polymorphism and risk of liver cirrhosis

Liu

Zhang

et al. 2015

Genet. Mol. Res.

View full text Add to dashboard Cite

show abstract

“…The relationship between cirrhosis development and TNF promoter has been investigated extensively (34,35,36,37). Although Romero-Gómez et al (38) found no association between polymorphism in -308 and the severity of fibrosis in HCV and Abdel-Latif found (11) in both fibrotic and cirrhotic cases, no significant correlation was observed in levels of matrix metalloproteinases (MMP)-2, MMP-9, and TNF-α between fibrotic and cirrhotic cases (39). TNF-α has been found higher in cirrhotic patients compared to CHC patients with no or mild fibrosis (40).…”

Section: Discussionmentioning

confidence: 99%

TNF-alpha 308 SNP Rs3091256 GG Genotype is Strongly Associated with Fibrosis in Patients with Chronic Hepatitis C

Günal¹,

Yalçin²,

Çelik³

et al. 2017

vhd

View full text Add to dashboard Cite

ÖZObjective: We aimed to review the influence of host genetic factors on the clinical course, treatment response as well as fibrosis progression in patients with viral hepatitis C genotype 1. Materials and Methods: Ninety-five patients with chronic hepatitis C virus (HCV) infection and 97 controls were enrolled. The patients received pegylated interferon (Peg-IFN)+ribavirin therapy for 48 weeks and were followed up for the next 48 weeks. Aspartat aminotransferase/platelet ratio (APRI) was used to detect liver fibrosis DNA specimens were extracted from the peripheral blood mononuclear cells and the tumor necrosis factor-alpha (TNF-α) 308 rs3091256 was genotyped by the polymerase chain reactionrestriction fragment length polymorphism method. Results: All patients included in the study were infected with HCV genotype 1. of the 95 HCV-positive patients, spontaneous viral clearence was observed in 25.5%, rapid viral response in 44.2%, early viral response in 91.8%, and sustained viral response was found in 73.3% of patients. The allele and genotype were not significant between patients and controls. There was no significant difference in virologic response as well. However, TNF-α-308 single nucleotide polymorphisms (SNP) rs3091256 GG genotype was strongly associated with fibrosis and alanine aminotransferase (ALT) levels (p=0.006 and p=0.017, respectively). Conclusion: TNF-α-308 polymorphisms may reveal different results among countries. Patients having SNP rs3091256 GG are prone to have higher ALT levels and fibrosis score but have better treatment outcome.

show abstract

Section: Supar As a Clinical Marker Of Inflammation And Organ Damagementioning

confidence: 99%

“…Further, it has been reported that it reflects overall immune activation and systemic inflammation [2]. suPAR has also emerged as a potential biomarker of fibrosis in chronic liver diseases of diverse etiology [10,11,[60][61][62].Recently, suPAR attracted significant attention in primary focal segmental glomerulosclerosis (FSGS). data from this pilot study revealed significantly higher suPAR levels among patients with moderately or highly elevated SDI after study inclusion, compared to patients without SDI increase (Figure 2).…”

mentioning

confidence: 99%

Soluble urokinase plasminogen activator receptor—A valuable biomarker in systemic lupus erythematosus?

Enocsson¹,

Sjöwall²,

Wetterö³

2015

Clinica Chimica Acta

View full text Add to dashboard Cite

The expression of uPAR is mainly regulated by growth factors and pro-inflammatory cytokines like basic fibroblast growth factor, epidermal growth factor, tumor necrosis factor, interleukin ( suPAR as a clinical marker of inflammation and organ damagePlasma membrane expression of uPAR as well as the levels of circulating suPAR have been investigated in relation to a broad range of conditions and suPAR has been referred to as a "molecular crystal ball" due to its prognostic value in diseases like tuberculosis, HIV, sepsis and cancer [2,6,13,26,58,59]. Further, it has been reported that it reflects overall immune activation and systemic inflammation [2]. suPAR has also emerged as a potential biomarker of fibrosis in chronic liver diseases of diverse etiology [10,11,[60][61][62].Recently, suPAR attracted significant attention in primary focal segmental glomerulosclerosis (FSGS). data from this pilot study revealed significantly higher suPAR levels among patients with moderately or highly elevated SDI after study inclusion, compared to patients without SDI increase (Figure 2).Furthermore, there were higher death rates among patients in the two groups with SDI increase (Figure 2). However, it is well known that present organ damage predicts further organ damage [17,100], and thus, adjustment for SDI at baseline should be performed to reduce the risk of bias. A stepwise linear multiple regression analysis was therefore performed to evaluate the impact of suPAR on future SDI increase. After adjusting for age, sex and SDI at study inclusion, we found suPAR levels to have a significant impact on future SDI increase (p = 0.005, standardized β = 0.20) whereas SDI at study inclusion was excluded from the model. Since recent studies have revealed an inverse correlation between serum suPAR and glomerular filtration [67,68,96], we also included estimated glomerular filtration (eGFR) (calculated by the 4-variable Modification of Diet in Renal Disease StudyGroup formula [101]) in the analysis, but eGFR was not retained in the model. From these results, we suggest that suPAR can actually predict organ damage independent of present SDI score or eGFR, but that a prospective study examining the association between suPAR levels at the time of diagnosis with future SDI would be preferable.In line with these findings, elevated suPAR levels have previously been demonstrated to associate with the risk of developing cancer, cardiovascular disease and type 2 diabetes later in life in the general population [7]. Importantly, these associations were independent of CRP, which is known for its predictive value in cardiovascular disease [7,102].7 Potential roles of suPAR in SLE pathogenesisAssessment of circulating suPAR levels at the clinical laboratory could possibly become a future way to estimate organ damage in SLE, and suPAR would be an even more appealing biomarker candidate if the levels could be mechanistically linked to the disease. The pathogenesis of SLE is notoriously complex and not fully understood, but includes disturbances in t...

show abstract

Twelve potential fibrosis markers to differentiate mild liver fibrosis from cirrhosis in patients infected with chronic hepatitis C genotype 1

Cited by 34 publications

References 29 publications

Interleukin-10 gene promoter polymorphism and risk of liver cirrhosis

Interleukin-10 gene promoter polymorphism and risk of liver cirrhosis

TNF-alpha 308 SNP Rs3091256 GG Genotype is Strongly Associated with Fibrosis in Patients with Chronic Hepatitis C

Soluble urokinase plasminogen activator receptor—A valuable biomarker in systemic lupus erythematosus?

Contact Info

Product

Resources

About